Jazz Pharmaceuticals plc reported second quarter 2026 financial results on August 3, 2026, announcing record total revenues of $1.2 billion, a 16% increase year-over-year. The company raised its full-year 2026 revenue guidance to $4.60–$4.75 billion from the previous range of $4.25–$4.50 billion. Key product performance included Xywav net sales of $471 million (up 13%) with 525 new patients, Epidiolex/Epidyolex sales of $292 million (up 16%), and Zepzelca sales of $106 million (up 42%). The firm generated $824 million in cash from operations during the first half of 2026 and repaid $1.0 billion in senior notes in June. Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing therapies for rare diseases, including sleep disorders, epilepsy, and cancer.
